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Optimizing methods for genital specimen collection to accurately characterize mucosal
immune responses is a priority for the HIV prevention field. The menstrual cup (MC) has
been proposed as an alternative to other methods including cervicovaginal lavage (CVL),
but no study has yet formally compared these two methods.
Methods
Forty HIV-infected, antiretroviral therapy-naïve women from the CAPRISA 002 acute HIV
infection cohort study were randomized to have genital fluid collected using the MC with
subsequent CVL, or by CVL alone. Qualitative data, which assessed levels of comfort and
acceptability of MC using a 5-point Likert scale, was collected. Luminex multiplex assays
were used to measure HIV-specific IgG against multiple gene products and 48 cytokines.
Results
The majority (94%) of participants indicated that insertion, wearing and removal of the MC
was comfortable. Nineteen MCs with 18 matching, subsequent CVLs and 20 randomized
CVLs were available for analysis. Mucosal IgG responses against four HIV-antigens were
detected in 99% of MCs compared to only 80% of randomized CVLs (p = 0.029). Higher
specific antibody activity and total antibodies were observed in MCs compared to CVL (all
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p<0.001). In MCs, 42/48 (88%) cytokines were in the detectable range in all participants
compared to 27/48 (54%) in CVL (p<0.001). Concentrations of 22/41 cytokines (53.7%)
were significantly higher in fluid collected by MC. Both total IgG (r = 0.63; p = 0.005) and
cytokine concentrations (r = 0.90; p<0.001) correlated strongly between MC and corre-
sponding post-MC CVL.
Conclusions
MC sampling improves the detection of mucosal cytokines and antibodies, particularly
those present at low concentrations. MC may therefore represent an ideal tool to assess
immunological parameters in genital secretions, without interfering with concurrent collec-
tion of conventional CVL samples.
Introduction
Elucidation of local immune responses in the genital mucosa is key to informing the design of
effective biomedical interventions that prevent the spread of HIV and other sexually transmit-
ted infections (STIs). Given the heterogeneity in the quality of mucosal samples obtained
through different sampling procedures, methods improving the detection of immune media-
tors and soluble immune markers in the cervicovaginal compartment need to be optimized
and verified across different studies and settings [1]. The benefits and shortfalls of several
methods for mucosal sample collection have been compared [2–7] and newer methods of geni-
tal mucosal sampling require rigorous comparison with conventional methods for the quantifi-
cation of antibodies, soluble proteins, and innate anti-microbial factors.
Swab, sponge or cervicovaginal lavage (CVL) sampling is among the conventional methods
used to collect cervicovaginal secretions. Specimens collected by Weck-cells, sno-strips, or oph-
thalmic sponges yield consistently higher concentrations of immune markers than CVL sam-
pling [3]. Generally, sponges have been shown to yield higher concentrations of measured
markers compared to more dilute specimen types such as CVL, but are also subject to a high
degree of variability in the amount of genital fluid collected [2,8,9]. Even among the various
types of sponges used to sample the cervix, certain sponges were shown to have superior sam-
ple recovery [10,11].
Several factors that should be considered for optimal sample collection include reproduc-
ibility, biological representativeness, minimum sample dilution, level of discomfort, invasive-
ness to the participant, ease of collection, and optimal recovery of target proteins, or cells from
the collection apparatus [8]. Genital mucosal self-sampling using menstrual cups (MC) or
other novel devices has been reported [7,12–15] and may be an attractive additional method or
replacement to CVL as it simplifies the collection procedure, and may circumvent the need for
clinician-driven genital sampling. Additionally, MC was well accepted and tolerated by clinical
trial participants who consented to a protocol requiring repeated mucosal sampling [6].
This randomized study compared the utility of MC and CVL sampling by assessing qualita-
tive data on comfort and acceptability of MC versus CVL, quantifying in each the immune fac-
tors associated with HIV, namely HIV-specific antibody titres and cytokine concentrations,
and the influence of mucosal sampling order on the detection of these markers.
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Methods
Study population and design
Since 2004, the CAPRISA 002 study has been following women from acute HIV infection at
two CAPRISA Clinical Research Sites in KwaZulu-Natal, South Africa [16]. On routine
CAPRISA 002 visits, 40 HIV-infected, antiretroviral therapy naïve women were offered to par-
ticipate in this randomized controlled study. Participants provided additional written informed
consent for the study. Women who were pregnant, menstruating, using intra-uterine devices,
or showed symptoms or signs of genitourinary tract infections were excluded from the study.
Twenty women were randomized to the MC (SoftCup, EuroFemPro, Netherlands, or the
SoftCup, Instead Inc., San Diego, CA) arm (Fig 1). This involved the vaginal insertion of a MC
by either a study clinician or nurse for a period of two hours. During this two hour period with
the inserted MC, participants proceeded with the routine study specific procedures including
for e.g. blood draws and clinical examination. Immediately after assisted removal of the MC by
the health professional, routine collection of CVL was performed. Participants carried on with
their routine study visit during this time. In the MC arm, one participant was excluded from
further evaluation due to menstrual blood contamination, and another participant did not pro-
vide a CVL specimen. Therefore, there were a total of 19 MC arm samples and 18 with match-
ing post-MC CVLs. A further 20 women were randomized to the CVL only arm of the study,
the current standard of sample collection in the CAPRISA 002 study. Questionnaires with
5-point Likert scales describing levels of comfort and acceptability were distributed to all
women from the MC arm after the procedure, and were collected after completion by the
participants.
Ethics Statement
The CAPRISA 002 study and this sub-study were both approved by the University of Kwa-
Zulu-Natal Biomedical Research Ethics Committee (Ref: E013/04 and BE114/12).
Fig 1. Schema of study design.
doi:10.1371/journal.pone.0131906.g001
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Menstrual cup and CVL collection and processing
After MCs were removed, they were placed into a labelled sterile 50ml conical tube and were
transported on ice to the CAPRISA Mucosal Immunology Laboratory for further processing
within 4–6 hours of collection. The MC was centrifuged at 2,000 rpm for 10 minutes at room
temperature [17]. The MC secretions were centrifuged as before to separate the mucous pellet
from the fluid supernatant. If the fluid supernatant dispersed into the solid mucous pellet, the
samples were centrifuged a third time. Phosphate buffered saline (PBS), was used to dilute the
clear supernatant fluid of the MC five-fold. A volume of 50 μl of the fluid supernatant obtained
after centrifugation was diluted with 200μl of PBS before storage at -80°C. On thawing, a fur-
ther five-fold dilution of sample was conducted using PBS, and the resultant 25-fold dilution
from the MC supernatant fraction was used in antibody and cytokine multiplex assays.
The CVLs were obtained and processed as previously reported [18,19]. Briefly, 5 ml of ster-
ile normal saline was used to bathe the cervix. The pooled fluids were subsequently aspirated
using a sterile plastic bulb pipette and dispensed into sterile conical tubes. Specimens were
transported on ice to the laboratory within 4–6 hours of collection. CVLs were centrifuged, and
the supernatants of approximately 1 ml each were stored at −80°C.
HIV-1-specific binding antibody assay
Antibodies against four HIV proteins were measured using a customized HIV-1 binding anti-
body multiplex assay (BAMA) [20], which included: consensus subtype C gp120, gp41 (Immu-
noDX, USA), p66 (RT) and p24 Gag (Protein Sciences Corporation, USA). A total of 5×106
carboxylated fluorescent beads (Bio-Rad Laboratories, Inc; Hercules, Ca, USA) were covalently
coupled to 25 μg of one of the purified HIV antigens and incubated with 1:50, 1:500, 1:1000
and 1:2000 dilutions of the MC specimens, or 1:20 up to 1:200 dilutions of the CVLs for detec-
tion of HIV-1 specific IgGs. These dilutions were necessary in order to detect the HIV-specific-
ities in the linear range of the standard curve. HIV-specific antibody IgGs were detected with
goat anti-human IgG (Southern Biotech, Birmingham, AL) conjugated to phycoerythrin at
4 μg/ml. Beads were then washed and antibody measurements were acquired on a Bio-Plex 200
multiplex system (Bio-Rad Laboratories, Inc; Hercules, Ca, USA), and was reported as a mean
fluorescent intensity (MFI). Background values (beads in the absence of detection antibody)
and normal human plasma were utilized as negative controls. All assays were run under good
clinical laboratory practice-compliant conditions, including tracking of positive controls by
Levy-Jennings charts consistent with other studies using customized BAMA [21–23]. Positivity
criteria for antibody-antigen pairs were pre-determined using a set of CVLs from 30 HIV-1
negative individuals [MFI standard deviation of 3] and a cut-off value of 100 MFI thereafter
determined a positive result.
IgG isotyping, total immunoglobulin quantification and HIV specific
activity
To control for the inter-subject variation in genital fluid recovery and normalize to total immu-
noglobulin concentrations, total IgG concentrations were measured in CVL samples. Although
MC collection volumes were less variable, total IgG levels were also measured in these samples.
Antibody subclasses IgG1, IgG2, IgG3, and IgG4 were quantified using total antibody isotyping
kits (Bio-Rad Laboratories, Inc; Hercules, Ca, USA) according to the manufacturer’s instruc-
tions, and the levels were determined by MFI plate readout on the Bio-Plex 200 multiplex sys-
tem). MC-derived supernatants were diluted from 1:200 up to 1:2000, and up to 1:200 for
CVLs in PBS to ensure that the MFIs for the HIV-specific antibodies were detected in the linear
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range of the standard curve. HIV-1 specific IgG activity in the CVL was calculated by deter-
mining the total amount of immunoglobulin in the assay for IgG1, IgG2, IgG3 and IgG4 in
ng/ml for each genital sample. Specific activity, the ratio of the MFI for each HIV-specific IgG
over total Ig (ng/ml), was calculated and adjusted for the dilution factor [log10 (MFI/ng ml
-1)].
The MFI obtained for the HIV-1 specific IgG was then divided by the total immunoglobulin
amount (MFIdilution/ng/ml) to give the IgG specific activity in order to adjust for varying
recovery volumes when performing CVLs. In addition, a second level cut-off for specific activ-
ity, based on HIV seronegative individuals, was applied to assess a positive response in the gen-
ital tract. Values falling below a detectable specific activity cut-off were included in the analysis
and assigned a value as one tenth of the value of the specific activity cut-off for each HIV-spe-
cific IgG.
Measurement of genital cytokine concentrations
The concentrations of 48 cytokines (Bio-Plex Pro Human Cytokine Group I 27-Plex Panel and
Group II 21-Plex Panel; Bio-Rad Laboratories, Inc; Hercules, Ca, USA) were measured in MC
and CVL specimens by Luminex multiplexing technology. Cytokines were measured in undi-
luted CVLs, and in a final 25-fold dilution in MC samples. The cytokine panel included the
pro-inflammatory, haematopoietic, regulatory, adaptive, and/or growth-related cytokines:
interleukin (IL)-1β, IL-1Rα, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12p70, IL-12p40,
IL-16, IL-18, IL-1α, IL-2Rα, IL-3, IL-13, IL-15, IL-17, basic fibroblast growth factor (FGF),
cutaneous T-cell attracting chemokine (CTACK), eotaxin, granulocyte colony-stimulating fac-
tor (G-CSF), granulocyte macrophage colony-stimulating factor (GM–CSF), growth regulated
(GRO)-α, hepatocyte growth factor (HGF), interferon (IFN)-γ, IFN-α2, interferon gamma-
induced protein (IP)-10, leukemia inhibitory factor (LIF), monocyte chemotactic protein
(MCP)-1, MCP-3, macrophage colony-stimulating factor (M-CSF), monokine induced by
gamma-Interferon (MIG), macrophage migration inhibitory factor (MIF), macrophage inflam-
matory protein (MIP)–1α, MIP-1β, nerve growth factor (NGF)-β, platelet derived growth fac-
tor (PDGF)-ββ, regulated upon activation normal T cell expressed and presumably secreted
(RANTES), stem cell factor (SCF), stem Cell Growth Factor (SCGF)-β, stromal derived factor
(SDF)-1α, tumor necrosis factor (TNF)–α, TNF-β, TNF-related apoptosis inducing ligand
(TRAIL), and vascular endothelial growth factor (VEGF) measured using Bio-Plex Pro Human
Cytokine kits and a Bio-Plex MagPix Array Reader (Bio-Rad Laboratories). The sensitivity of
these kits ranged between 0.2 and 45.2 pg/ml for each of the 48 cytokines measured. Data was
collected using Bio-Plex Manager software version 6, and a 5 PL regression formula was used
to calculate sample concentrations from the standard curves. Cytokine levels below the lower
limit of detection (LLOD) of the assay were reported as the mid-point between the lowest con-
centration measured for each cytokine and zero. To minimize the effect of inter-plate variabil-
ity, MC and CVL specimens from the same participant were analyzed on the same plate.
Statistical analysis
Basic descriptive statistics were used to characterize the participants. Differences between arms
were compared using Fisher’s exact test for categorical data or Mann-Whitney tests for contin-
uous data. Comparisons of HIV antibody specificities between groups were performed using
either Mann-Whitney tests for independent comparisons or Wilcoxon signed rank test for
paired samples. Fisher’s exact test was used to compare detectability of cytokine responses
between MC and randomized CVL samples. Pearson’s correlation was used to determine asso-
ciations between the matched MC and CVL samples, where values were log transformed to
ensure normality. The false discovery rate method was used to correct for multiple
Antibodies and Cytokines in CVL versus Menstrual Cup Secretions
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comparisons for both antibody and cytokine comparisons. P-values less than 0.05 were consid-
ered significant. Statistical analysis was performed using SAS version 9.3 (SAS Institute Inc.,
Cary) and graphs were drawn using GraphPad Prism 6 software.
Results
Baseline characteristics
The median age for women in the study was 29 years (interquartile range (IQR) 26–32 years)
and women had been HIV-infected for a median 60 months (IQR 51–70 months). Median
CD4 count and viral load at randomization were 558 cells/μl (IQR 448–734 cells/μl) and 4.05
log copies/ml (IQR 3.51–4.42 log copies/ml). Participant characteristics by study arm are sum-
marized in Table 1. There were no significant differences in age, time post-infection, use of
injectable contraception, CD4+ T cell counts, viral loads, or sexually transmitted infections
between women randomized to either receive a CVL alone or MC followed by a CVL.
Of the 19 women in the MC arm, nine (47.4%) were on depot medroxyprogesterone acetate
(DMPA) injectable contraception, one participant had a tubal ligation, while the remaining
nine women (47.4%) were not on any hormonal contraception. Of the 20 women in the CVL
only arm, 13 (65.0%) were on injectable contraception [DMPA (n = 11) and norethisterone
(n = 2)], while seven (35.0%) reported no contraceptive use (including one woman in meno-
pause). Of the 22 women on injectable contraception, irrespective of study arm, 15 (68.2%)
reported amenorrhoea.
Feasibility and Acceptability of Menstrual Cup Sampling
The median time that the MC was in place was 120 minutes (range 88–175 minutes). A total of
17/20 (85%) women in the MC arm returned the questionnaires about acceptability of the MC
sampling method. All of the women opted for the nurse or clinical practitioner to insert and
remove the MC. A majority (94%, 16/17) of participants answered that clinician insertion was
acceptable, that wearing the MC and removal was comfortable. All participants indicated their
willingness to wear a MC again, and all preferred to have the MC inserted instead of a specu-
lum. Nearly one third (29%) indicated that they would consider self-inserting the MC if ade-
quately trained, with 47% being unsure and 24% indicating that they did not want to self-insert
the MC.
Table 1. Characteristics of participants overall, and stratified by study arm.
Characteristic Overall (N = 39) MC arm (N = 19) CVL only arm (N = 20) p-value
Age (years); median (IQR) 29 (26–32) 29 (26–32) 28 (26–32) 0.502
Months post Infection; median (IQR) 60 (51–70) 60 (48–70) 60 (54–70) 0.559
CD4 T cell count (cells/μ); median (IQR) 558 (448–734) 606 (494–765) 507 (439–701) 0.367
Viral load (log copies/ml); median (IQR) 4.05 (3.51 4.42) 3.71 (2.55–4.47) 4.08 (3.72–4.38) 0.312
Injectable hormonal contraception; % (n) 56.4% (22) 47.4% (9) 65.0% (13) 0.341
Bacterial vaginosis; % (n/N) 14.3% (3/21) 27.3% (3/11) 0.0% (0/10) 0.214
T. vaginalis; % (n/N) 4.8% (1/21) 9.1% (1/11) 0.0% (0/10) 1.000
N. gonorrhoeae; % (n/N) 4.8% (1/21) 9.1% (1/11) 0.0% (0/10) 1.000
C. trachomatis; % (n/N) 19.1% (4/21) 27.3% (3/11) 10.0% (1/10) 0.587
M. genitalium; % (n/N) 14.3% (3/21) 9.1% (1/11) 20.0% (2/10) 0.589
Not all the study participants were tested for an STI or BV
doi:10.1371/journal.pone.0131906.t001
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Menstrual cup specimens yield higher HIV-1 specific and total antibody
levels than CVL specimens
Specific activity was compared between MCs and randomized CVLs in order to evaluate the
differences in magnitudes for the HIV-specific binding antibodies. As shown in Fig 2A–2D,
levels of p24, p66, gp41 and gp120-specific activities were significantly higher (all p<0.001) in
MCs than in randomized CVL samples. Total IgG levels were also higher in MCs compared to
randomized CVL samples (p<0.001) (Fig 3A). In addition, post-MC CVLs were measured for
total IgG and compared to those of randomized CVLs to investigate an impact on subsequent
levels of IgG secreted with prior MC sampling. Interestingly, while there was a trend towards
lower levels of total IgG in post-MC CVL samples, these were not significantly different to ran-
domized CVL levels (p = 0.096), suggesting minimal impact of prior MC sampling.
All of the MC samples (19/19) had detectable responses to p24, p66 and gp41, and 95% (18/
19) had detectable responses to gp120. In comparison, 85% (17/20) of randomized CVL sam-
ples had detectable responses for p66, gp41 and gp120, while only 65% (13/20) had detectable
responses to p24. Overall, the mucosal IgG responses against four HIV-antigens were
Fig 2. HIV specific activity [Log10 MFI*dilution factor ngml
-1 (MFI/total Ig)] for gag p24- 2A, p66- 2B, gp41- 2C and gp120- 2D in MC (n = 19) and
randomized CVL samples (n = 20). Limit of detection is shown as the dotted line on the figures.
doi:10.1371/journal.pone.0131906.g002
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significantly detected in 99% of MCs compared to only 80% of randomized CVLs (p = 0.029).
Within MCs, the magnitude of the HIV-specific IgG titres were similar for p24, p66(RT), and
gp41 MN. Compared to all the other specificities, however, the magnitude of gp120-specific
IgGs was significantly lower (p<0.001; S1A Fig).
In randomized CVLs, p24, gp41 and gp120 specific activities were significantly lower than
p66 (p<0.05- S1B Fig). These results show that the MC method may be more robust allowing
for detection of a similar range of magnitude across various HIV-specific IgGs compared to
CVL, where dilution is likely to affect sensitivity to detect certain humoral immune
specificities.
Total and specific HIV antibodies correlate between menstrual cup and
post- menstrual cup CVL
To determine whether the magnitudes of the antibodies in the MC correlated with the subse-
quent matched CVL samples, the total antibody between the two samples was compared. Total
IgG titres correlated strongly within the same participants (r = 0.63, p = 0.005) (Fig 3B).
Of the four HIV-specificities measured in this study, MC concentrations of p24 (r = 0.72;
p = 0.001), and gp120 (r = 0.54; p = 0.022) (Fig 3C and 3F) correlated significantly with
matched post-MC CVL samples, while gp41 (r = 0.21; p = 0.395) and p66 (r = 0.36; p = 0.138)
did not (Fig 3D and 3E).
HIV-specific activity in post-menstrual cup CVL sampling is comparable
to randomized CVL
Mucosal sampling by CVL post-MC was compared to the randomized CVL. There were no sig-
nificant differences in total IgG (p = 0.096) (Fig 3A) and HIV specific activity for gp41
(p = 0.211), gp120 (p = 0.132) and p66 (p = 0.090), while p24 (p = 0.019) was significantly
higher in the post-MC CVL compared to the randomized CVL sample (S2A–S2D Fig).
Genital cytokines are more frequently detected in Menstrual Cup fluid
than in randomized CVL specimens
The detectability of 48 cytokines were compared in genital secretions from women randomized
to the MC (n = 19) versus CVL arms (n = 20; Table 2). Cytokines were more frequently
detected in MC specimens (42/48 cytokines observed above LLOD) compared to CVL (26/48
cytokines above LLOD; p<0.001). Twenty-five of the 48 cytokines assessed were consistently
observed above the LLOD in both MC and CVL. Of the remaining 23, one, IL-12p40, was
detected in 95%MC specimens versus 100% CVL specimens; and 17 were observed in 100% of
MC specimens, but not CVL specimens: IL-4, IL-13, TNF-α, 35%; IL-5, 45%; IL-2, G-CSF,
IFN-γ 50%; PDGF-ββ, 60%; RANTES, 70%; IL-7, IP-10, 75%; IL-9, 80%; MIP-1α, 90%; and
SCF, IL-12p70, Il-17, IL-8, in 95% CVL specimens (Table 2). Eleven of these 23 cytokines
remained statistically different between sampling methods after multiple comparisons adjust-
ment, all detected more frequently in MC specimens than CVL. Cytokines with concentrations
below the LLOD in40% of participants were classified as categorical variables for analyses of
Fig 3. Comparison of total antibody (ngml-1) in MCs (n = 19)- 3A, randomized CVL (n = 20) andmatched post-MC CVLs (n = 18) [Log10 MFI*dilution
factor ngml-1 (MFI/total Ig)]- Correlation plots between total antibody in MCs andmatched post MC CVLs- 3B. Correlation plots (Fig 3C–3F) of HIV
specific activity in MCs (n = 18) and matched post-MC CVLs (n = 18) [Log10 MFI*dilution factor ng ml
-1 (MFI/total Ig)] for gag p24- 3C, p66- 3D, gp41- 3E and
gp120- 3F.
doi:10.1371/journal.pone.0131906.g003
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Table 2. Comparison of cytokine concentrations and detection frequencies in genital fluid isolated frommenstrual cups and CVLs in a rando-
mised study.
Menstrual Cup (n = 19) Randomized CVL (n = 20)
Analyte Median(pg/ml) IQR(pg/ml) LLOD(%) Median(pg/ml) IQR(pg/ml) LLOD(%) Fold difference p-valuec p-valued
Eotaxin 17.5 5.4–30.8 15.8 0.2 0.2–0.2 90.0 85.1 <0.001§ <0.001§
IL-13 3.1 1.9–6.5 0.0 0.1 0.1–0.8 65.0 36.0 <0.001§ <0.001§
IL-4 1.6 0.9–2.0 0.0 0.1 0.1–0.6 65.0 20.7 <0.001§ <0.001§
IFN-γ 67.6 37.6–176.7 0.0 3.5 1.8–22.1 50.0 19.3 <0.001§ <0.001§
PDGF-ββ 42.7 32.4–79.7 0.0 2.9 0.2–17.3 40.0 14.6 <0.001§ 0.003§
MCP-3 122.1 80.1–166.5 5.3 8.7 8.7–29.8 60.0 14.1 <0.001§ <0.001§
IL-7 5.0 3.1–11.1 0.0 0.7 0.1–1.9 25.0 7.6 <0.001§ 0.047
IL-9 7.3 3.7–10.1 0.0 1.2 0.8–4.5 20.0 5.9 <0.001§ 0.106
TNF-β 3.5 2.2–4.8 0.0 1.5 0.8–1.7 0.0 2.3 <0.001§ N/A
IFN-α2 65.1 55.4–82.3 0.0 35.1 24.1–48.9 0.0 1.9 <0.001§ N/A
TNF-α 26.6 15.6–86.6 0.0 0.6 0.6–9.7 65.0 42.5 <0.001§ <0.001§
HGF 803.5 381.3–1986.1 0.0 31.0 24.0–355.2 0.0 26.0 <0.001§ N/A
IL-6 15.1 5.3–51.7 0.0 0.8 0.5–4.7 0.0 19.6 <0.001§ N/A
M-CSF 575.0 280.6–997.8 0.0 102.4 29.9–242.9 0.0 5.6 <0.001§ N/A
SDF-1α 340.9 174.1–606.9 0.0 81.6 51.1–126.2 0.0 4.2 <0.001§ N/A
IL-17 62.1 39.6–114.4 0.0 18.6 12.1–32.5 5.0 3.3 <0.001§ 1.000
IL-16 86.0 56.1–116.3 0.0 33.3 12.2–49.7 0.0 2.6 <0.001§ N/A
IL-2Rα 78.3 44.4–102.7 0.0 35.1 23.6–56.4 0.0 2.2 <0.001§ N/A
IL-5 0.6 0.4–3.5 0.0 0.0 0.0–0.6 55.0 6300 0.002§ <0.001§
G-CSF 1225.4 280.4–3678.4 0.0 18.9 1.7–441.9 50.0 64.8 0.002§ <0.001§
IL-2 4.6 2.1–15.0 0.0 0.8 0.0–3.2 50.0 6.0 0.002§ <0.001§
b-NGF 1.4 0.6–2.2 5.3 0.4 0.2–0.9 10.0 3.6 0.003§ 1.000
MCP-1 38.8 22.2–99.9 0.0 7.1 6.1–15.3 0.0 5.4 0.003§ N/A
IL-8 966.5 533.8–7947.1 0.0 41.5 9.9–671.5 5.0 23.3 0.004§ 1.000
SCF 22.7 15.1–73.4 0.0 8.8 3.9–21.0 5.0 2.6 0.004§ 1.000
VEGF 1255.6 689.3–3578.2 0.0 371.6 149.5–1020.1 0.0 3.4 0.004§ N/A
LIF 42.0 25.5–55.0 0.0 15.7 10.9–26.0 0.0 2.7 0.004§ N/A
FGF basic 36.7 24.1–43.6 0.0 19.9 14.3–24.1 0.0 1.8 0.004§ N/A
IL-18 1967.0 406.2–3172.1 0.0 102.9 17.0–1352.7 0.0 19.1 0.005§ N/A
MIP-1α 1.9 1.5–4.1 0.0 0.7 0.4–2.2 10.0 2.8 0.006§ 0.487
MIG 46850. 2823.7–19683.5 0.0 1275.8 111.0–4158.4 0.0 3.7 0.006§ N/A
IL-3 164.9 99.1–223.7 0.0 101.4 73.4–117.9 0.0 1.6 0.006§ N/A
IP-10 1342.5 119.0–10423.2 0.0 94.8 6.3–742.7 25.0 14.2 0.009§ 0.047
GROα 464.7 314.4–730.6 0.0 43.8 35.3–485.7 0.0 10.6 0.009§ N/A
IL-1β 393.9 57.7–1754.9 0.0 18.5 5.0–274.6 0.0 21.3 0.013§ N/A
IL-12p70 90.0 22.8–130.2 0.0 36.6 9.3–75.0 5.0 2.5 0.017§ 1.000
MIP-1β 12.1 8.0–55.9 0.0 4.9 2.6–16.8 0.0 2.5 0.021§ N/A
IL-1α 276.7 192.6–1000.5 0.0 155.8 32.8–404.5 0.0 1.8 0.023§ N/A
RANTES 13.5 5.2–22.3 0.0 5.6 0.4–9.0 30.0 2.4 0.024§ 0.020§
TRAIL 77.9 48.7–235.8 0.0 20.1 8.3–122.9 0.0 3.9 0.026§ N/A
IL-12p40 194.8 96.0–423.7 5.3 360.1 318.3–441.1 0.0 0.5 0.031§ 0.487
SCGF-β 19.8 19.8–68.1 68.4 19.8 19.8–19.8 95.0 1.0 0.039§ 0.044
GM-CSF 38.3 28.9–118.2 0.0 107.1 96.4–112.8 0.0 0.4 0.046 N/A
IL-15 1.5 0.3–5.0 21.1 6.4 3.1–11.9 20.0 0.2 0.057 1.000
IL-1rα 22096.4 1594.3–33497.0 0.0 5673.2 1592.7–13686.3 0.0 3.9 0.069 N/A
(Continued)
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detectable concentrations. This occurred in 1/48 (2.1%) cytokines assessed in MC specimens
compared to 11/48 (22.9%) cytokines assessed in CVL specimens (p = 0.004).
Menstrual cup specimens yield greater cytokine concentrations
With the exception of IL-15, IL-10, CTACK, MIF, IL-1Rα, and IL-12p40, the median concen-
trations of 41/48 cytokines were significantly higher in MC than randomized CVL specimens
(Table 2). Only one of these 41 cytokines, GM-CSF, did not maintain statistical significance
after FDR adjustment. IL-12p40 concentrations were greater in the randomized CVL than
menstrual cup samples (median 360.1pg/ml in CVL vs 194.8 in MC, p = 0.031) while IL-15, IL-
10, CTACK, MIF, and IL-1Rα were not different between samples.
Menstrual cup sampling does not alter the cytokine milieu
The median cytokine concentrations in randomised MC specimens were similarly ranked to
that isolated from randomised CVL specimens (Spearman r = 0.85, 95% CI 0.74–0.92;
p<0.001; Fig 4A), indicating a similar profile of cytokines isolated from MC and CVL speci-
mens. This trend was also observed when comparing the median cytokine concentrations in
CVL sampled immediately after MC removal (n = 18) with that of matching MC specimens
(Spearman r = 0.903, 95% CI 0.83–0.95, p<0.001; Fig 4B). Furthermore, comparing cytokine
concentrations in CVL collected after MC sampling (n = 18) with CVLs collected from women
randomised to undergo CVL sampling alone (n = 20), 47/48 cytokines measured were similar
in concentration, further supporting the observation that CVL sampling immediately after MC
removal does not significantly alter the cytokine profile. Only CTACK concentrations differed
between groups (p<0.001), being 38% lower in CVL sampled after MC (median 26.6 pg/ml,
IQR 14.5–34.4 pg/ml) compared to CVL sampled alone (42.8 pg/ml, IQR 31.7–50.2 pg/ml).
Conclusions
This first randomized study comparing MC and CVL mucosal sampling has shown that MC
sampling is a superior and preferred method for the collection of immune markers than the
conventional CVL sampling. MC sampling consistently allowed for more frequent detection
and reliable quantification of HIV-specific IgGs and cytokines, demonstrating the superior
sensitivity of this method over CVL sampling, in particular for markers present at low concen-
trations. In addition, this study also demonstrated that MC insertion did not significantly
impact the immune environment when the subsequent CVL was analysed.
Table 2. (Continued)
Menstrual Cup (n = 19) Randomized CVL (n = 20)
Analyte Median(pg/ml) IQR(pg/ml) LLOD(%) Median(pg/ml) IQR(pg/ml) LLOD(%) Fold difference p-valuec p-valued
IL-10 19.0 3.3–31.6 0.0 11.1 7.2–20.0 0.0 1.7 0.405 N/A
CTACK 48.3 33.7–62.7 0.0 42.8 33.4–49.6 0.0 1.1 0.452 N/A
MIF 1601.9 354.1–5255.9 0.0 361.0 60.2–11069.8 0.0 4.4 0.802 N/A
aIQR: Interquartile range.
bLLOD: Lower limit of detection.
cMann-Whitney U tests were conducted to compare non-parametric unpaired data.
dFisher’s exact tests were conducted to compare detection frequencies.
§Significant P-value after FDR multiple comparison adjustment.
doi:10.1371/journal.pone.0131906.t002
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Further benefits of MC sampling extend from the acquisition of concentrated genital fluid
where the precise dilution can be calculated from the original fluid. The neat sample obtained
fromMC can be diluted substantially more than CVLs for the detection of humoral responses
in particular, and these dilutions can be modified for the different sensitivities for various
assays and to generate consistent data.
While this study provided a substantial description of the HIV-specific antibody and genital
cytokine milieu detectable in genital secretions isolated fromMC and CVL, the experimental
assays conducted were not exhaustive. Further investigation into sampling-associated differ-
ences using additional assays could verify the impact of MC sampling on the genital cellular
environment, epithelial barrier integrity, broader antibody profile and other factors. These
would also facilitate interpretation of isolated differences between sampling approaches such as
the reduction in both MC IL-12p40 and post-MC CVL CTACK concentrations relative to ran-
domised CVL specimens.
Multiple studies have compared humoral and innate immune markers using various collec-
tion methods including Weck-Cel or Merocel sponges, swabs and ophthalmic sponges, and
CVL. These methods were found to yield differing results for the detection and concentrations
of immune markers [5,24,25]; although Merocel sponges were found to yield superior quality
and quantity of immune markers than Dacron or flocked nylon swabs [11], other studies have
shown that flocked swabs were superior to Dacron swabs for detection of STIs [26,27]. In addi-
tion, variability in the detection of immune markers can be introduced by sampling different
areas of the genital tract [28], or through inter-individual variability [2,4,8]. Concern that MC
sampling may include secretions from the cervical os and surrounding vaginal walls that may
be absent from CVL is mitigated by this study’s observation of similar profiles of both antibod-
ies and cytokines in MC and CVL. Furthermore, while the drawback for most of these methods
is the reliance on healthcare professionals, MCs can be self-inserted and removed with appro-
priate training [12,13]. The MC circumvents the disadvantages of the more common swab or
lavage methods, including the need for speculum insertion, dilution [8] and inconsistent
Fig 4. Comparison of median cytokine concentrations observed in genital fluid isolated from CVL, MC andmatching subsequent CVL specimens
in a randomised study.Cytokine concentrations were compared in genital fluid isolated from n = 19 MC- 4A and n = 20 randomized CVL, and n = 18
matching MC and subsequently-sampled CVL specimens- 4B. The concentrations of 48 cytokines [(regulatory ; growth factor✚; haematopoietic✖;
adaptive ◆; inflammatory ●)] were determined in each specimen by luminex technology and the median of each cytokine concentration was compared by
Spearman rank correlation. Data are depicted on Log10 scales. P-values <0.05 were considered significant.
doi:10.1371/journal.pone.0131906.g004
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genital fluid recovery [5,29]. In this study participants had some reservations to self-insert or
remove the MC. However, considering the high acceptability of wearing the device and the
commercial availability as a self-insertion device, the study team believe that with additional
counselling and education, including the use of short videos on insertion and removal of the
MC, this method could quickly become more user-friendly. Studies have reported that with
training, self-sampling using MCs or other devices can be used successfully [6,12–14]. A single
study by Boskey et al. (2003) with n = 16 participants in the USA, showed that a 5 second self-
insertion of the MC yielded an average of 0.5g of cervicovaginal fluid secretions [13]. Beyond
this study a wide range of expert opinions exist recommending anything from insertion with
immediate removal to overnight placement [13,17]. In addition, other factors like hormonal
contraceptive use were not reported in the Boskey study. Hormonal contraception (56% in our
study) is an important factor that could affect the quality [30] and yield of genital secretions.
The rationale for the insertion of the MC for two hours therefore was a compromise between
taking into account expert opinions and practicality of participant follow-up. A shorter sam-
pling time with the MC may be beneficial to maintaining mucosal sample integrity by reducing
the time of exposure of the vaginal vault, which is a hypoxic environment, to the MC. MC
would be an ideal tool to collect undiluted vaginal secretions [15] in future vaccine trials and
HIV prevention research to better measure and define mucosal correlates of immune protec-
tion that have thus far been described mainly in the highly exposed uninfected populations
[31–39], an area that remains a significant gap in HIV research.
A limitation of this study was that menstrual history data was not available for all partici-
pants, and therefore prevented the assessment of the role of the menstrual cycle on the volume
and composition of genital fluid. However, the random allocation of women to the sampling
methods would have minimized a possible selection bias. Another limitation is that total vol-
ume of genital secretions recovered from the MC was not measured, however, post-collection
weighing of the secretions in the MC is a suitable alternative [13]. A possible caveat to this
method is that the weights of the MCs themselves could vary between the batches which may
over- or under-estimate the weight of the secretions and may likely incur logistical problems in
large-scale studies. In addition, while antibody measurements were adjusted by total IgG in
both specimens, no similar method of standardisation, for example, lithium chloride [9,40] or
the bicinchoninic acid adjustments [3], was conducted for cytokine evaluations. This would
have been particularly useful in CVL specimens where absolute dilution factor is not known.
However, to standardize the cytokine concentrations observed in MC and CVL, specimens
were not adjusted for dilution factors since the dilution of genital fluid in saline as collected by
CVL sampling was not known. Despite this, the cytokine multiplex assays allowed the quantifi-
cation of a diverse panel of soluble immune markers that mirrored the trends observed in the
normalised antibody assays.
In conclusion, MC collection represents a convenient and more practical alternative to
other genital sample collection methods such as CVL, and may circumvent the need for health-
care professional driven genital sampling. MC is a robust tool for the detection and quantifica-
tion for humoral and soluble biomarkers and can be used to more accurately study immune
responses in genital secretions. It will be important to assess their utility for genital mucosal
sampling in vaccine trials to identify immune correlates of protection. If warranted and given
the practicality, MC could be widely implemented in the field.
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